Evidence map›Paper›PMID 37936209›Full record

ArticleStem cell research & therapy2023

Induced pluripotent stem cells derived from patients carrying mitochondrial mutations exhibit altered bioenergetics and aberrant differentiation potential.

Fibi Meshrkey, Kelly M Scheulin, Christopher M Littlejohn, Joshua Stabach, Bibhuti Saikia, Vedant Thorat, Yimin Huang, Thomas LaFramboise, Edward J Lesnefsky, Raj R Rao and 2 more

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Disease models of Leigh syndrome: From yeast to organoids.Journal of inherited metabolic disease · 2024
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Fibi Meshrkey *Department of Biological Sciences, J. William Fulbright College of Arts and Sciences, University of Arkansas, Science and Engineering 601, Fayetteville, AR, 72701, USA.
Kelly M Scheulin *Regenerative Bioscience Center, University of Georgia, Athens, GA, USA.
Christopher M LittlejohnRegenerative Bioscience Center, University of Georgia, Athens, GA, USA.
Joshua StabachDepartment of Biological Sciences, J. William Fulbright College of Arts and Sciences, University of Arkansas, Science and Engineering 601, Fayetteville, AR, 72701, USA.
Bibhuti SaikiaDepartment of Biological Sciences, J. William Fulbright College of Arts and Sciences, University of Arkansas, Science and Engineering 601, Fayetteville, AR, 72701, USA.
Vedant ThoratDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Yimin HuangDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Thomas LaFramboiseDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Edward J LesnefskyDepartment of Physiology and Biophysics, Virginia Commonwealth University, Richmond, VA, USA.
Raj R RaoDepartment of Biomedical Engineering, College of Engineering, University of Arkansas, Fayetteville, AR, USA.
Franklin D WestRegenerative Bioscience Center, University of Georgia, Athens, GA, USA.
Shilpa IyerDepartment of Biological Sciences, J. William Fulbright College of Arts and Sciences, University of Arkansas, Science and Engineering 601, Fayetteville, AR, 72701, USA. si012@uark.edu.ORCID 0000-0001-6287-2232
University of Arkansas at Fayetteville · USUniversity of Georgia · USUniversity School · USVirginia Commonwealth University · US

Funding

THE CANCER EPITOPE DATABASE AND ANALYSIS RESOURCEU24CA248138 · NCI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI PETERS, BJOERN, SETTE, ALESSANDRO · 2021 to 2025
$4.6M
Metabolic regulation of MODS in pediatric mitochondrial disordersR01HD110536 · NICHD · UNIVERSITY OF ARKANSAS AT FAYETTEVILLE · PI Shilpa Iyer · 2023 to 2026
$2.5M
Mechanisms of lincDUSP Oncogenic Effects in Colon CancerR01CA217992 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI LAFRAMBOISE, THOMAS LOUIS · 2018 to 2023
$1.8M
Tools and Data for Bayesian Modeling of Mitochondrial Genome Dynamics in Human DiseaseR01LM013067 · NLM · CASE WESTERN RESERVE UNIVERSITY · PI BRYNJARSDOTTIR, JENNY, LAFRAMBOISE, THOMAS LOUIS · 2020 to 2024
$1.5M
mtDNA heteroplasmy in development and differentiation: an in-vitro approachR15NS080157 · NINDS · VIRGINIA COMMONWEALTH UNIVERSITY · PI IYER, SHILPA · 2013 to 2013
$352k
BLRD VA I01 BX001355NCI NIH HHS R01 CA217992NCI NIH HHS U24 CA248138NICHD NIH HHS R01 HD110536NINDS NIH HHS R15 NS080157NLM NIH HHS R01 LM013067
6 · The paper itself

Abstract

backgroundHuman mitochondrial DNA mutations are associated with common to rare mitochondrial disorders, which are multisystemic with complex clinical pathologies. The pathologies of these diseases are poorly understood and have no FDA-approved treatments leading to symptom management. Leigh syndrome (LS) is a pediatric mitochondrial disorder that affects the central nervous system during early development and causes death in infancy. Since there are no adequate models for understanding the rapid fatality associated with LS, human-induced pluripotent stem cell (hiPSC) technology has been recognized as a useful approach to generate patient-specific stem cells for disease modeling and understanding the origins of the phenotype.

methodshiPSCs were generated from control BJ and four disease fibroblast lines using a cocktail of non-modified reprogramming and immune evasion mRNAs and microRNAs. Expression of hiPSC-associated intracellular and cell surface markers was identified by immunofluorescence and flow cytometry. Karyotyping of hiPSCs was performed with cytogenetic analysis. Sanger and next-generation sequencing were used to detect and quantify the mutation in all hiPSCs. The mitochondrial respiration ability and glycolytic function were measured by the Seahorse Bioscience XFe96 extracellular flux analyzer.

resultsReprogrammed hiPSCs expressed pluripotent stem cell markers including transcription factors POU5F1, NANOG and SOX2 and cell surface markers SSEA4, TRA-1-60 and TRA-1-81 at the protein level. Sanger sequencing analysis confirmed the presence of mutations in all reprogrammed hiPSCs. Next-generation sequencing demonstrated the variable presence of mutant mtDNA in reprogrammed hiPSCs. Cytogenetic analyses confirmed the presence of normal karyotype in all reprogrammed hiPSCs. Patient-derived hiPSCs demonstrated decreased maximal mitochondrial respiration, while mitochondrial ATP production was not significantly different between the control and disease hiPSCs. In line with low maximal respiration, the spare respiratory capacity was lower in all the disease hiPSCs. The hiPSCs also demonstrated neural and cardiac differentiation potential.

conclusionOverall, the hiPSCs exhibited variable mitochondrial dysfunction that may alter their differentiation potential and provide key insights into clinically relevant developmental perturbations.

Indexed as

Induced Pluripotent Stem CellsPluripotent Stem CellsCell DifferentiationChildEnergy MetabolismHumansMutationBioenergeticsDifferentiationhiPSCMitochondrial diseasePluripotent stem cellReprogrammingRespiration

Identifiers

PMID37936209
PMCPMC10631039
OpenAlexW4388464827

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.